CD52相关文献与解析，生知库 | 链接生命科学的每一步

Protective role of soluble CD52 in obesity-associated steatotic liver disease and glucose dysregulation in mice

可溶性CD52在小鼠肥胖相关脂肪肝疾病和葡萄糖代谢紊乱中的保护作用

doi:10.1016/j.molmet.2025.102279

Miyazawa, Yuichiro; Wada, Tsutomu; Iwasa, Yuichi; Fuse, Kento; Shioneri, Hisafumi; Onogi, Yasuhiro; Sameshima, Azusa; Yoshida, Tomoyuki; Takasaki, Ichiro; Mori, Hisashi; Koizumi, Keiichi; Tsuneki, Hiroshi; Saito, Shigeru; Sasaoka, Toshiyasu

Causal Implication of CD52-Driven Immune Dysregulation in Sarcopenic Obesity: Integrating Mendelian Randomization and Multiomics Profiling

CD52驱动的免疫失调在肌少症性肥胖中的因果关系：整合孟德尔随机化和多组学分析

期刊:Clinical Interventions in Aging

影响因子:3.7

doi:10.2147/CIA.S570497

Xuekelati, Saiyare; Abulitifu, Yilihamu; Maimaitiwusiman, Zhuoya; Xu, Lei; Guo, Shuke; Xu, Qihong; Ke, Jiayu; Wang, Hongmei

Region-specific transcriptomic responses to CD52 deficiency in the male reproductive tract

男性生殖道中CD52缺陷引起的区域特异性转录组反应

期刊:BMC Genomics

影响因子:3.7

doi:10.1186/s12864-026-12652-8

Kang, Huifang; Zhu, Yulong; Fu, Chunzheng; Wang, Hao; Groenen, Martien A M; Hua, Guoying; Huang, Lei; Crooijmans, Richard P M A

EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8(+) T cell dysfunction in neuroblastoma

EDF1加速神经节苷脂GD3的积累，从而增强神经母细胞瘤中CD52介导的CD8(+) T细胞功能障碍。

期刊:Journal of Experimental & Clinical Cancer Research

影响因子:12.8

doi:10.1186/s13046-025-03307-9

Li, Di; Li, Meng; Zhuo, Zhenjian; Guo, Huiqin; Zhang, Weixin; Xu, Yile; Wang, Hai-Yun; Liu, Jiabin; Xia, Huimin; Lin, Huiran; Tang, Jue; He, Jing; Miao, Lei

The molecular basis of immunosuppression by soluble CD52 is defined by interactions of N-linked and O-linked glycans with HMGB1 box B.

可溶性 CD52 免疫抑制的分子基础是由 N-连接和 O-连接聚糖与 HMGB1 盒 B 的相互作用决定的。

期刊:Journal of Biological Chemistry

影响因子:3.9

doi:10.1016/j.jbc.2025.108350

Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer.

NUF2 和 CD52 表达升高预示着非小细胞肺癌对铂类化疗药物的耐药性和不良预后。

期刊:Discover Oncology

影响因子:2.9

doi:10.1007/s12672-025-03809-0

Liu Bo, Lu Zhansheng, Yao Jing

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

表面 CD52、CD84 和 PTGER2 标记来自癌症患者和 G-CSF 治疗供体的成熟 PMN-MDSC。

期刊:Cell Reports Medicine

影响因子:11.7

doi:10.1016/j.xcrm.2023.101380

Francesca Pettinella,Barbara Mariotti,Chiara Lattanzi,Kirsten Bruderek,Marta Donini,Sara Costa,Olivia Marini,Giulia Iannoto,Sara Gasperini,Elena Caveggion,Monica Castellucci,Federica Calzetti,Francisco Bianchetto-Aguilera,Elisa Gardiman,Matteo Giani,Stefano Dusi,Maurizio Cantini,Aurora Vassanelli,Denise Pavone,Michele Milella,Sara Pilotto,Pamela Biondani,Benedikt Höing,Marie Carolin Schleupner,Timon Hussain,Boris Hadaschik,Cordelia Kaspar,Carlo Visco,Cristina Tecchio,Leo Koenderman,Flavia Bazzoni,Nicola Tamassia,Sven Brandau,Marco A Cassatella,Patrizia Scapini

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis

Gatralimab（一种新一代人源化抗CD52单克隆抗体）在进行性多发性硬化症患者中的I期试验

期刊:Neurology and Therapy

影响因子:4.8

doi:10.1007/s40120-024-00659-w

Albach, Fredrik N; Geier, Christian; Keicher, Christian; Posch, Maximilian G; Schreiber, Stephan J; Grütz, Gerald; Akyüz, Levent; Luo, Xiaodong; Le-Halpere, Annaig; Truffinet, Philippe; Wagner, Frank

Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab

甲氨蝶呤、氢化可的松、长春新碱、索布唑沙和依托泊苷是阿仑单抗再治疗后CD52表达缺失的复发性T细胞前淋巴细胞白血病的一种有效治疗选择

期刊:JMA Journal

影响因子:1.8

doi:10.31662/jmaj.2024-0145

Ikeda, Shohei; Suzuki, Manabu; Sukegawa, Masumi; Tsunoda, Saburo; Ohta, Masatsugu

CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.

CD52 通过巨噬细胞 Siglec-G 发出信号，是癌症免疫疗法的治疗靶点。

Protective role of soluble CD52 in obesity-associated steatotic liver disease and glucose dysregulation in mice

可溶性CD52在小鼠肥胖相关脂肪肝疾病和葡萄糖代谢紊乱中的保护作用

Causal Implication of CD52-Driven Immune Dysregulation in Sarcopenic Obesity: Integrating Mendelian Randomization and Multiomics Profiling

CD52驱动的免疫失调在肌少症性肥胖中的因果关系：整合孟德尔随机化和多组学分析

Region-specific transcriptomic responses to CD52 deficiency in the male reproductive tract

男性生殖道中CD52缺陷引起的区域特异性转录组反应

EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8(+) T cell dysfunction in neuroblastoma

EDF1加速神经节苷脂GD3的积累，从而增强神经母细胞瘤中CD52介导的CD8(+) T细胞功能障碍。

The molecular basis of immunosuppression by soluble CD52 is defined by interactions of N-linked and O-linked glycans with HMGB1 box B.

可溶性 CD52 免疫抑制的分子基础是由 N-连接和 O-连接聚糖与 HMGB1 盒 B 的相互作用决定的。

Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer.

NUF2 和 CD52 表达升高预示着非小细胞肺癌对铂类化疗药物的耐药性和不良预后。

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

表面 CD52、CD84 和 PTGER2 标记来自癌症患者和 G-CSF 治疗供体的成熟 PMN-MDSC。

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis

Gatralimab（一种新一代人源化抗CD52单克隆抗体）在进行性多发性硬化症患者中的I期试验

Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab

甲氨蝶呤、氢化可的松、长春新碱、索布唑沙和依托泊苷是阿仑单抗再治疗后CD52表达缺失的复发性T细胞前淋巴细胞白血病的一种有效治疗选择